Latest News
Tango Therapeutics, Inc.
- Tango Therapeutics, Inc. Estimates – NASDAQ:TNGX
- Tango builds on Revolution Medicines’ pancreatic cancer success
- How Tango Improved On Revolution's 'Unprecedented' Results
- Tango Therapeutics stock falls despite positive cancer trial data
- Tango Therapeutics reports pancreatic cancer trial data By Investing.com
- Form 8K Tango Therapeutics Inc For: 23 October By Investing.com
- Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
- Tango Therapeutics to present pancreatic cancer study data By Investing.com
- JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data
- Tango Therapeutics R&D president Adam Crystal sells $660,796 in shares
- Tango therapeutics R&D president Adam Crystal sells $660k in shares.
- Tango Therapeutics principal accounting officer sells $198k in stock
Headlines from the last 30 days, linking to the original publishers. See all market news →